



## FOR IMMEDIATE RELEASE

### CONTACT:

Nick Wasmiller

SeyferthPR

1-800-435-9539

[wasmiller@seyferthpr.com](mailto:wasmiller@seyferthpr.com)

### **METABOLIC SOLUTIONS DEVELOPMENT COMPANY PRESIDENT AND CO-FOUNDER TO SPEAK AT DIABETES SUMMIT**

KALAMAZOO, MICH. (March 7, 2011) – Metabolic Solutions Development Company (MSDC) President and Co-Founder Jerry Colca, Ph.D. will speak on “PPAR-sparing insulin sensitizers: A new hope for the treatment of type 2 diabetes” as part of a panel discussion entitled “Diabetes and the Metabolic Syndrome Drug Development” on Tuesday, March 8 at 8 a.m. at the Diabetes Summit in Philadelphia.

Joining Colca on the panel is William Washburn of Bristol-Myers Squibb; Paul Burton of Johnson & Johnson; Jeffrey Pfefferkorn of Pfizer; and Jerome J. Schentag of the University at Buffalo. The fourth annual Diabetes Summit is hosted by the GTCbio, a division of the Global Technology Community.

MSDC is a clinical-stage company developing innovative therapeutics to treat diabetes. The company’s lead candidate, MSDC-0160, is currently in a 90-day, multinational Phase 2b study involving more than 420 patients throughout the United States and India. A Phase 2a trial of MSDC-0160 demonstrated that it can improve insulin sensitivity and lower blood glucose levels in humans without the side effects of the current market-leading diabetes medicines.

# # #

#### ***About Metabolic Solutions Development Company (MSDC)***

*Metabolic Solutions Development Company ([www.msdrx.com](http://www.msdrx.com)) is a drug discovery and development company exploiting novel molecular targets to develop new therapies for metabolic diseases associated with altered mitochondrial function, especially insulin resistance and type 2 diabetes. The company has raised nearly \$50 million in support of the development of its pioneer and lead products, MSDC-0160 and MSDC-0602, which are new insulin sensitizers that work through a novel mitochondrial molecular mechanism of action and which have been shown to be effective in reducing fasting plasma glucose without the unwanted side effects associated with PPAR $\gamma$  activation. Founded in 2006 by former Pfizer researchers Jerry Colca, Ph.D. and Rolf Kletzien, Ph.D., MSDC is headquartered in Kalamazoo, Mich.*